Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia

Twenty-five patients with myeloproliferative diseases were treated with pegylated interferon alpha-2b. Prior to therapy, 15/25 patients had a JAK2(V617F) mutation. Eight JAK2-positive patients were on therapy in hematological complete remission at 24 months. Five of eight patients demonstrated a 1.2...

Full description

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 91; no. 9; pp. 1281 - 1282
Main Authors Samuelsson, J, Mutschler, M, Birgegard, G, Gram-Hansen, P, Bjorkholm, M, Pahl, HL
Format Journal Article
LanguageEnglish
Published Italy 01.09.2006
Subjects
Adult
Aged
Female
Humans
Interferon-alpha - therapeutic use
Janus Kinase 2
Male
MEDICIN
Medicin och hälsovetenskap
MEDICINE
Middle Aged
Mutation
Myeloproliferative Disorders - drug therapy
Myeloproliferative Disorders - enzymology
Myeloproliferative Disorders - genetics
Polycythemia Vera - drug therapy
Polycythemia Vera - enzymology
Polycythemia Vera - genetics
Polyethylene Glycols
Protein-Tyrosine Kinases - genetics
Proto-Oncogene Proteins - genetics
Recombinant Proteins
Thrombocythemia, Essential - drug therapy
Thrombocythemia, Essential - enzymology
Thrombocythemia, Essential - genetics
Treatment Outcome
Online AccessGet full text

Cover

More Information
Summary:Twenty-five patients with myeloproliferative diseases were treated with pegylated interferon alpha-2b. Prior to therapy, 15/25 patients had a JAK2(V617F) mutation. Eight JAK2-positive patients were on therapy in hematological complete remission at 24 months. Five of eight patients demonstrated a 1.2-3.6 fold reduction in the percentage of JAK2(V617F) cells.
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Feature-1
ObjectType-Correspondence-3
ISSN:0390-6078
1592-8721
1592-8721